Aurora Spine Announces Publication of REFINE Study's 12-Month Results in the International Journal of Spine Surgery

Aurora Spine publishes 12-month clinical study results for its ZIP™ spinal implant system.

What the company is saying

Aurora Spine Corporation is highlighting the peer-reviewed publication of the REFINE study's 12-month results in the International Journal of Spine Surgery, focusing on its ZIP™ MIS Interlaminar Fusion System. The company frames this as a key milestone in building a clinical evidence base to support physician adoption and patient care. Executive commentary from President and CEO Trent Northcutt, CTO Laszlo Garamszegi, and CCO Matt Goldstone emphasizes the importance of prospective, multicenter data and the company's ongoing commitment to clinical research. External validation is provided by Steven Falowski, MD, and Jason Pope, MD, both of whom participated in or supported the study, underscoring the multidisciplinary nature of the research. The announcement positions the publication as a resource for clinicians and as evidence of Aurora Spine's dedication to supporting the ZIP platform. The tone is confident, focusing on the value of clinical follow-up and peer-reviewed evidence, but does not disclose specific patient outcomes or commercial impact.

What the data suggests

The announcement confirms that the REFINE study, a prospective, observational, open-label, nonrandomized, multicenter clinical investigation, has completed 12 months of patient follow-up and that its results were published online on October 9, 2026. The study evaluated the ZIP™ MIS Interlaminar Fusion System in patients with symptomatic neurogenic claudication and lumbar spinal stenosis with degenerative disc disease, involving both spine surgeons and interventional pain specialists as investigators. The only quantitative data disclosed are the 12-month duration and the publication date; no patient numbers, outcome metrics, or comparative results are provided. The evidence is limited to the fact of publication and the study design, with no insight into clinical efficacy, safety, or commercial adoption. The disclosure is complete regarding the publication event but lacks operational or financial performance data, making it impossible to assess the impact on company trajectory or market adoption from this release alone.

Analysis

The announcement reports the publication of 12-month results from the REFINE study, a prospective, multicenter clinical investigation of Aurora Spine's ZIP™ MIS Interlaminar Fusion System. The tone is positive, emphasizing the company's commitment to clinical evidence and support for physicians, but the core factual content is the publication itself—a routine milestone in medical device development. No financial, operational, or patient outcome data are disclosed, and there are no claims of commercial adoption or revenue impact. Forward-looking statements are limited to general aspirations about supporting the ZIP platform and informing future research, not specific projections or unsubstantiated claims. There is no mention of capital outlay or long-dated benefits, and the event (publication) is already realised. The language is proportionate to the milestone, with no exaggeration of impact or overstatement of future benefits.

Risk flags

• ●The absence of disclosed patient outcome data or enrollment numbers means investors cannot assess the clinical effectiveness or safety profile of the ZIP™ system based on this announcement. This limits the ability to gauge the technology's competitive positioning or likelihood of widespread adoption.
• ●No commercial, regulatory, or reimbursement milestones are discussed, leaving uncertainty about the pathway from clinical publication to revenue generation. The announcement does not address whether the study results will influence payer coverage or drive sales.
• ●Reliance on peer-reviewed publication as a milestone, without supporting data or next-step guidance, creates a risk that the impact of this event is more symbolic than material for near-term financial performance.

Bottom line

Aurora Spine has achieved a routine but necessary milestone by publishing 12-month results from its REFINE clinical study on the ZIP™ MIS Interlaminar Fusion System, with the article now available in a peer-reviewed journal. While this adds credibility and may support discussions with clinicians and payers, the announcement does not provide any patient outcome data, enrollment figures, or evidence of commercial traction. The event is already realised, and its immediate value is limited to reputational and scientific standing rather than direct financial impact. Investors should recognize that while clinical publication is a prerequisite for adoption, the lack of disclosed efficacy or safety results means the commercial outlook remains unclear. The most important takeaway is that Aurora Spine is progressing through the clinical validation process, but actionable investment insight will require future disclosures of outcome data or commercial adoption metrics.

Announcement summary

(TSXV: ASG) (OTCQB: ASAPF) Aurora Spine Corporation announced the publication of the REFINE study's 12-month results in the International Journal of Spine Surgery. The REFINE study is a prospective, observational, open-label, nonrandomized, multicenter study evaluating Aurora Spine's ZIP™ MIS Interlaminar Fusion System. The study focused on patients with symptomatic neurogenic claudication associated with lumbar spinal stenosis and degenerative disc disease. Both spine surgeons and interventional pain specialists participated as investigators in the study. The 12-month results were published online on October 9, 2026. Trent Northcutt, President and Chief Executive Officer of Aurora Spine, stated that building a meaningful clinical evidence base is central to the company's commitment to physicians and patients. Steven Falowski, MD, co-Principal Investigator and Functional Neurosurgeon at Argires-Marotti Neurosurgical Associates of Lancaster, PA, commented that following patients over 12 months is important to understanding their experience beyond the initial procedure. Jason Pope, MD, President and Chief Executive Officer of Evolve Restorative Center, represented the Contract Research Organization that supported the study and noted Aurora Spine's commitment to acquiring prospective, 12-month data for this novel treatment. Laszlo Garamszegi, Chief Technology Officer of Aurora Spine, emphasized that the REFINE publication is an important part of the process for ZIP and that prospective clinical follow-up helps evaluate technology performance in clinical practice. Matt Goldstone, Chief Commercial Officer of Aurora Spine, stated that the REFINE publication provides an additional resource for clinicians and reflects the company's commitment to supporting the ZIP platform with clinical research. The article is titled: "A Prospective, Observational, Open-Label, Nonrandomized, Multicenter Study Measuring Functional Outcomes in a Novel Interspinous Stabilization Device in Patients With Low Back Pain: 12-Month Results for the REFINE Study." The publication is available through the International Journal of Spine Surgery, DOI: 10.14444/8969.

Disagree with this article?